Donanemab in Alzheimer’s disease: Promise,limitations,and implementation challenges in Australia

Abstract

Get full access to this article

View all access options for this article.

References

Sims

Zimmer

Evans

, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023; 330(6): 512–527, Available from: https://pubmed.ncbi.nlm.nih.gov/37459141/

Sato

Niimi

Ihara

, et al. Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer’s disease in Japan. Alzheimers Res Ther 2024; 16(1): 205, Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11448067/

Filippi

Cecchetti

Spinelli

, et al. Amyloid-related imaging abnormalities and β-Amyloid-Targeting antibodies: a systematic review. JAMA Neurol 2022; 79(3): 291–304, Available from: https://pubmed.ncbi.nlm.nih.gov/35099507/

Urso

Introna

Gnoni

, et al. Donanemab eligibility in early Alzheimer’s disease: a real-world study. J Alzheimers Dis 2025; 105(3): 745–750, Available from: https://www.researchgate.net/publication/391396219_Donanemab_eligibility_in_early_Alzheimer’s_disease_A_real-world_study

Livingston

Huntley

Liu

, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission. Lancet 2024; 404(10452): 572–628, Available from: https://pubmed.ncbi.nlm.nih.gov/39096926/